In the early era without anti-HER2 targeted therapy, HER2-overexpressing breast cancer had a higher risk of recurrence and an even worse prognosis than triple-negative breast cancer, with suboptimal resistance to postoperative radiotherapy. Here, ERBB2 is linked to triple-negative breast carcinoma.